Jan 23, 2009: Commentary (1 of 2): Dose-dense paclitaxel for advanced ovarian cancer : The Lancet

Note: may require registration (free):
"The results of the JGOG (Japanese) trial in ovarian cancer (Oct 17, p 1331) show a significant benefit in terms of progression-free survival in the group on adjuvant weekly high-dose paclitaxel. Such improvements are in the magnitude of those achieved by the introduction of platinum compounds. However, some features of the JGOG study should be highlighted...."